Bellvitge translational imaging biomarkers group (TRIBIO)
PRINCIPAL INVESTIGATORS
- Marina Suárez Piñera
- Gabriel Reynés Llompart
CLINICAL RESEARCHERS
- Pablo Naval Baudín
- Maria Teresa Bajen Lazaro
- Mª Eugenia De Lama Salvador
- Amadeo Muntane Sanchez
- Ana Benitez Segura
- Laura Rodriguez Bel
- Jaume Mora Salvado
- Maria Àngels De Miquel Miquel
- María Esther Alba Rey
- Laura Maria Gracia Sanchez
- Juan Jose Martín Marcuartu
- Javier Jesús Robles Barba
- Michal Pudis
POSTDOCTORAL RESEARCHERS
- José Luis Vercher Conejero
- Ignacio Martinez Zalacain
- Paloma Mora Montoya
SCIENTIFIC SUPPORT
- Alvaro Espigares Santiago
MANAGEMENT SUPPORT
- Jaqueline Quispe Bravo
- Eva Orive Romero
Translational Medicine
Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention
Scientific production
22
PAPERS
Average IF: 4,35
18
LED PAPERS
Average IF: 3,5
3 PUBLICATIONS IN FIRST DECILE
11 PUBLICATIONS IN FIRST QUARTILE
15 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Garcia Ruiz,A;Pons Escoda,A;Grussu,F;Naval Baudin,P;Monreal Aguero,C;Hermann,G;Karunamuni,R et al, An accessible deep learning tool for voxel-wise classification of brain malignancies from perfusion MRI, Cell Rep Med, 2024;5(3):101464-101464, doi:10.1016/j.xcrm.2024.101464
- Villanueva,B;Sánchez Corral,MÁ;Alba,E;Ordi,Q;Ruiz,Y;Torres Iglesias,R;Portillo,A et al, Long-term follow-up of hereditary hemorrhagic telangiectasia patients without significant pulmonary right-to-left shunt at screening., Eur. J. Intern. Med., 2024;132106-112, doi:10.1016/j.ejim.2024.12.006
- Duminy Luppi,D;Alcaide Aldeano,A;Planas Cerezales,L;Bermudo,G;Vicens Zygmunt,V;Luburich,P;Del Rio Carrero,B et al, Diagnostic and prognostic implications of family history of fibrotic interstitial lung diseases, Respir Res, 2024;25(1):433-433, doi:10.1186/s12931-024-03063-y
- Pons Escoda,A;Garcia Ruiz,A;Naval Baudin,P;Martinez Zalacain,I;Castell,J;Camins,A;Vidal,N et al, Differentiating IDH-mutant astrocytomas and 1p19q-codeleted oligodendrogliomas using DSC-PWI: high performance through cerebral blood volume and percentage of signal recovery percentiles, Eur Radiol, 2024;34(8):5320-5330, doi:10.1007/s00330-024-10611-z
- Falo,C;Azcarate,J;Fernandez Gonzalez,S;Perez,X;Petit,A;Perez,H;Vethencourt,A et al, Breast Cancer Patient’s Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II-III Disease, Cancers, 2024;16(13):doi:10.3390/cancers16132421
Research highlights
PROJECTS
1 Granted competitive project
2 Ongoing competitive projects
5 Started clinical trials
9 Ongoing clinical trials
NETWORKS
SENR
Selected projects
- 2020-003959-16. Estudio de fase iII para evaluar la capacidad diagnóstica de la PET con [18F]-CTT1057 en pacientes con cáncer de próstata con aumento de los niveles del PSA (Recurrencia Bioquímica [RB]) (GUIDEPATH). Novartis Farmacéutica, S.A. Budget: 148.523€. 2021- . PI: Javier Jesús Robles Barba.
- CI24-10486. MSPredict: MS Prognosis through Advanced Imaging Analysis. FUNDACIÓ “LA CAIXA”. Budget: 50.000€. 2024-2026. PI: NAVAL BAUDÍN, PABLO.
- Estudio dosimétrico en los pacientes tratados con [177Lu]Lu-PSMA-617. Sociedad Española de Medicina Nuclear e Imagen Molecular (SEMNIM). Budget: 25.000€. 2023-2025. PI: MARTÍN MARCUARTU, JUAN JOSE.
- OSPREY01. ONCOSIL PANCREATIC CANCER POST-MARKETING CLINICAL REGISTRY. OncoSil Medical Ltd. Budget: 9.660€. 2024- . PI: JUAN JOSE MARTÍN MARCUARTU.
- amber SEL-P-01. SAFETY AND EFFICACY OF AMBER PERIPHERAL LIQUID EMBOLIC SYSTEM: A FIRST-IN-HUMAN & PIVOTAL STUDY. LVD Biotech S.L. Budget: 8.000€. 2024- . PI: Elena Serrano Alcalá.